3D Bioplotter Research Papers

Displaying all papers about Epilepsy (3 results)

3D-Printing with precise layer-wise dose adjustments for paediatric use via pressure-assisted microsyringe printing

European Journal of Pharmaceutics and Biopharmaceutics 2020 Volume 157, Pages 59-65

The establishment of 3D-printing as manufacturing process for oral solid dosage forms enables new options for the individualized medicine. The aim of this work was to develop a novel drug-printing model using pressure-assisted microsyringe (PAM) technology, which allows the precise dispensing of drug substances. Printed tablets with different numbers of layers, mimicking different doses for pediatric subgroups, were analyzed regarding mass variation, friability, thickness and disintegration time. Furthermore, the uniformity of dosage units and the dissolution behavior were investigated. Friability was

Investigation of semi-solid formulations for 3D printing of drugs after prolonged storage to mimic real-life applications

European Journal of Pharmaceutical Sciences 2020 Volume 146, Article 105266

The implementation of tailor-made dosage forms is currently one of the biggest challenges in the health sector. Over the last years, different approaches have been introduced to provide an individual and precise dispensing of the appropriate dose of an active pharmaceutical ingredient (API). A more recent approach, which has been intensively researched in the last years, is 3D-printing of medicines. The aim of this work was to develop printing formulations free of organic solvents for a pressure-assisted microsyringe printing method (PAM), which should also be printable over several days of storage. Furthermore, the printed dosage forms should provide a sustained…

Valproate release from polycaprolactone implants prepared by 3D-bioplotting

Die Pharmazie - An International Journal of Pharmaceutical Sciences 2011 Volume 66, Number 7, Pages 511-516

In this study we examined the release kinetics of valproate from polycaprolactone (PCL) implants constructed for local antiepileptic therapy. The PCL implants were produced with a novel 3D-Bioplotting technology. Release kinetics were determined by superfusion of these implants. Valproate was measured in the superfusate fractions with high pressure liquid chromatography (HPLC). The HPLC measurements were linear over a concentration range of 10-500 g/mL for valproate and the limit of quantification was found to be 9 g/mL. The HPLC method used is simple, accurate and sensitive. Within the first day, valproate (10%w/w)-PCL implants released already 77% of the maximum possible liberated…